<p>INDILIV (Individualized Immunosuppression after Liver Transplant) Beyond Year 1: </p>
<figure class="table">
<table class="table table-bordered">         <tbody>             <tr class="table-secondary">
                <td>
                    &nbsp;
                </td>
                <td>
                    <strong>Low Risk&nbsp;</strong>
                </td>
                <td>
                    <strong>Medium Risk&nbsp;</strong>
                </td>
                <td>
                    <strong>High Risk&nbsp;</strong>
                </td>
            </tr>
            <tr>
                <td>
                    <strong>Inflammation¹&nbsp;</strong>
                </td>
                <td>
                    <p style="text-align:center;">
                        –&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        +&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        + and&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    <strong>DSA&nbsp;</strong>
                </td>
                <td>
                    <p style="text-align:center;">
                        – / +&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        –&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        +&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    <strong>Fibrosis ≥ F2&nbsp;</strong>
                </td>
                <td>
                    <p style="text-align:center;">
                        –&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        –&nbsp;
                    </p>
                </td>
                <td>
                    <p style="text-align:center;">
                        +&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    <strong>Year 2–3&nbsp;</strong>
                </td>
                <td>
                    Tacrolimus 3–5 ng/mL&nbsp;
                </td>
                <td>
                    <p>
                        Tacrolimus 3–5 ng/mL  
                    </p>
                    <p>
                        Mycophenolate 360 mg BID&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tacrolimus 5–8 ng/mL  
                    </p>
                    <p>
                        Mycophenolate 360–540 mg BID²&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    <strong>Beyond Year 3&nbsp;</strong>
                </td>
                <td>
                    Tacrolimus 3–5 ng/mL&nbsp;
                </td>
                <td>
                    <p>
                        Tacrolimus 3–5 ng/mL  
                    </p>
                    <p>
                        Mycophenolate 360 mg BID&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tacrolimus 5–8 ng/mL  
                    </p>
                    <p>
                        Mycophenolate 360–540 mg BID³&nbsp;
                    </p>
                </td>
            </tr>
        </tbody>
    </table>
</figure>

<p>
    Footnotes:
</p>
<ol>
    <li data-list-item-id="ea6fbb14e356af33410a90051629dc32c">
         Inflammation assessed via histology (BANFF-mini): mild portal inflammation with no interface, vascular, or biliary changes.
    </li>
    <li data-list-item-id="ed7f41d5288f5f0c61eddef4354b6cdf7">
         Consider switching to sirolimus 3–8 ng/mL if covered and fibrosis &gt;F2 but not in MASH (metabolic-associated steatohepatitis).
    </li>
    <li data-list-item-id="e035d7daf03027dd850ee3c5346aace87">
         Consider adding steroids if no histologic improvement is observed.
    </li>
    <li data-list-item-id="e9f238ce9c0552d219ce7b110e2c4c043">
         Patients with moderate/severe early TCMR (T-cell mediated rejection) or late TCMR (&gt;3 months post-transplant) are at medium to high risk and should be managed cautiously after biopsy.
    </li>
</ol>
<p>
    Routine Follow-Up Schedule (Years 1, 3, 5):
</p>
<ul>
    <li data-list-item-id="e8e0686acc6f8a3701f97f3f971b72a81">
         Bloodwork: ALT, AST, ALP, INR, bilirubin, creatinine (GFR), LDL, HbA1c
    </li>
    <li data-list-item-id="e35698ba48fe5b0963a733cee3be3333d">
         Urine: Albumin-to-creatinine ratio (UACR)
    </li>
    <li data-list-item-id="ee252635639ba648b8fae5b6f3c5dc114">
         HBV serology if transplanted for HBV
    </li>
    <li data-list-item-id="e840887a952fa5dbd8a5f26e3c6033550">
         Fibroscan
    </li>
    <li data-list-item-id="e8a7897add2399295c4af45995558c394">
         Liver biopsy:
        <ul>
            <li data-list-item-id="ec7f680bf9c941bd47ec68f0d25612e9d">
                 Strongly recommended at Years 1, 3, 5 with DSAs. &nbsp;
            </li>
            <li data-list-item-id="e9663041cdbce7bd5e5b80fc6ba354a80">
                 If biopsy timing differs, adjust immunosuppression (IS) by only one step at a time.
            </li>
            <li data-list-item-id="e3ad3fef8d8348b5ef22610046f3e4d0e">
                 Expected findings from protocol biopsies:
                <ul>
                    <li data-list-item-id="e3623e05ad4168dd9d47bdc7443b47f14">
                         Low risk: 20%
                    </li>
                    <li data-list-item-id="ea59ea4de7a3f4660e3bf917623898103">
                         Medium risk: 50%
                    </li>
                    <li data-list-item-id="e611fd6c51c4c0ef6acf6cde3f98f7e48">
                         High risk: 30%
                    </li>
                </ul>
            </li>
        </ul>
    </li>
</ul>
<p>
    Biopsy should always be obtained:
</p>
<ul>
    <li data-list-item-id="e23b7ce9274a6ae1db1431c4f2dbd57cf">
         Before reducing IS to monotherapy or CNI-free regimens.
    </li>
    <li data-list-item-id="ed58f129983e3a3d6e28568a287f9c5a1">
         1–2 years after major IS reduction.
    </li>
    <li data-list-item-id="e94dc3adeedd8ac3e918a01fc640ac004">
         With ALT elevation and DSA positivity
    </li>
    <li data-list-item-id="e779234289c777c850150c0b2fa100fcf">
         de novo DSA.
    </li>
    <li data-list-item-id="ebc9f43aac556ceba2ce1ed472ceeb827">
         After moderate/severe early or late TCMR (&gt;3 months)
    </li>
    <li data-list-item-id="eddab8cda3ccf529732f09120b0cbe951">
         If ALT remains elevated on multiple occasions
    </li>
    <li data-list-item-id="e603b222c153aaa57056713fe950c84c5">
         If liver stiffness ≥7kPa or DSA present.
    </li>
</ul>
<p>
    Safety notes:
</p>
<ul>
    <li data-list-item-id="ea777c9013950daaffa61b682ac8cd79a">
         Protocol biopsies are safe unless intrahepatic bile ducts are dilated.
    </li>
    <li data-list-item-id="e7a11a7ca7452c2bafc9fba8affb20cd3">
         Rule out bile duct dilatation with pre-biopsy ultrasound, especially with ALP elevation or prior biliary strictures.
    </li>
    <li data-list-item-id="eb8eaa8ceac140caa5bcfba78ab72b585">
         LDLT patients have a higher likelihood of ductal dilatation and mobile grafts—maintain low threshold for ultrasound.&nbsp;
    </li>
</ul>